These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 1364024)
21. Adjuvant effect of Cliptox on the protective immune response induced by an inactivated vaccine against foot and mouth disease virus in mice. Batista A; Quattrocchi V; Olivera V; Langellotti C; Pappalardo JS; Di Giacomo S; Mongini C; Portuondo D; Zamorano P Vaccine; 2010 Aug; 28(38):6361-6. PubMed ID: 20637310 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the potency for cattle of trivalent FMD vaccines adjuvanted by aluminum hydroxide-saponin or oil emulsion. Barei S; Panina GF; Orfei Z; Nardelli L; Castelli S Zentralbl Veterinarmed B; 1979 Aug; 26(6):454-60. PubMed ID: 232342 [No Abstract] [Full Text] [Related]
23. The administration of foot and mouth disease vaccine with oil adjuvant and its influence on the diagnosis of bovine tuberculosis. Nader A; López B; Lázaro L; Errico F; Ritacco V; Grotter CG; de Kantor IN Rev Sci Tech; 1992 Sep; 11(3):785-96. PubMed ID: 1335306 [TBL] [Abstract][Full Text] [Related]
24. Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats. Park ME; Lee SY; Kim RH; Ko MK; Lee KN; Kim SM; Kim BK; Lee JS; Kim B; Park JH Vaccine; 2014 Sep; 32(40):5221-7. PubMed ID: 25066738 [TBL] [Abstract][Full Text] [Related]
25. Antibody response in bovine pharyngeal fluid following foot-and-mouth disease vaccination and, or, exposure to live virus. Francis MJ; Ouldridge EJ; Black L Res Vet Sci; 1983 Sep; 35(2):206-10. PubMed ID: 6314460 [TBL] [Abstract][Full Text] [Related]
26. Production and application of recombinant antibodies to foot-and-mouth disease virus non-structural protein 3ABC. Foord AJ; Muller JD; Yu M; Wang LF; Heine HG J Immunol Methods; 2007 Apr; 321(1-2):142-51. PubMed ID: 17328909 [TBL] [Abstract][Full Text] [Related]
27. Foot-and-mouth disease polyvalent oil vaccines inoculated repeteadly in cattle do not induce detectable antibodies to non-structural proteins when evaluated by various assays. Espinoza AM; Maradei E; Mattion N; Cadenazzi G; Maddonni G; Robiolo B; La Torre J; Bellinzoni R; Smitsaart E Vaccine; 2004 Nov; 23(1):69-77. PubMed ID: 15519709 [TBL] [Abstract][Full Text] [Related]
29. Guinea pig protection test as indicator of potency of oil emulsion foot-and-mouth disease vaccines. Black L; Pullen L; Boge A Res Vet Sci; 1985 Sep; 39(2):207-11. PubMed ID: 2999930 [TBL] [Abstract][Full Text] [Related]
30. [Testing the effectiveness of foot-and-mouth disease vaccines: the relationship between test infection results and corresponding neutralization titers of vaccinated cattle]. Bengelsdorff HJ Berl Munch Tierarztl Wochenschr; 1989 Jun; 102(6):193-8. PubMed ID: 2548473 [TBL] [Abstract][Full Text] [Related]
31. [Comparison of various methods for the measurement of the humoral immune response in mice vaccinated with aphthous fever virus]. Feledi CA; Pujol CA; Arese A; Piccone ME; Marcovecchio F; Zuloaga G; Massouh EJ Rev Argent Microbiol; 1992; 24(3-4):126-35. PubMed ID: 1338879 [TBL] [Abstract][Full Text] [Related]
32. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine. Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008 [TBL] [Abstract][Full Text] [Related]
33. Development of an epitope-blocking-enzyme-linked immunosorbent assay to differentiate between animals infected with and vaccinated against foot-and-mouth disease virus. Oem JK; Chang BS; Joo HD; Yang MY; Kim GJ; Park JY; Ko YJ; Kim YJ; Park JH; Joo YS J Virol Methods; 2007 Jun; 142(1-2):174-81. PubMed ID: 17336400 [TBL] [Abstract][Full Text] [Related]
34. Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle. Fowler VL; Paton DJ; Rieder E; Barnett PV Vaccine; 2008 Apr; 26(16):1982-9. PubMed ID: 18342409 [TBL] [Abstract][Full Text] [Related]
35. Detection of carriers of foot-and-mouth disease virus among vaccinated cattle. Moonen P; Jacobs L; Crienen A; Dekker A Vet Microbiol; 2004 Nov; 103(3-4):151-60. PubMed ID: 15504586 [TBL] [Abstract][Full Text] [Related]
36. The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease. Dunn CS; Samuel AR; Pullen LA; Anderson J Virology; 1998 Jul; 247(1):51-61. PubMed ID: 9683571 [TBL] [Abstract][Full Text] [Related]
37. Cedivac-FMD can be used according to a marker vaccine principle. Chénard G; Selman P; Dekker A Vet Microbiol; 2008 Apr; 128(1-2):65-71. PubMed ID: 18035508 [TBL] [Abstract][Full Text] [Related]
38. [The effectiveness of foot-and-mouth disease vaccines in Switzerland. I. Screening tests and herd immunity]. Müller HK; Villinger F; Griot C; Ackermann M; Bruckner L; Kihm U Schweiz Arch Tierheilkd; 1989; 131(7):379-86. PubMed ID: 2552579 [TBL] [Abstract][Full Text] [Related]
39. Experiments on the preparations and testing of associated vaccine against foot and mouth disease and vesicular disease in swine. Mitev G; Tekerlekov P; Dilovsky M; Ognianov D; Nikolova E Arch Exp Veterinarmed; 1978; 32(1):29-33. PubMed ID: 27158 [TBL] [Abstract][Full Text] [Related]
40. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs. Du Y; Dai J; Li Y; Li C; Qi J; Duan S; Jiang P Vet Immunol Immunopathol; 2008 Aug; 124(3-4):274-83. PubMed ID: 18511133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]